technetium tc-99m medronate kit
Small moleculeapprovedImaging agent
Approved
Dec 16, 1977
Clinical trial activity
3 trials · 7 clinical orgs · 5 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
1
Phase 4
1
Earliest trial started Mar 1, 2010 (NCT00956163)
Timeline
1970s
- Dec 16, 1977
Pharmalucence — Earliest FDA Approval
- Dec 16, 1977
Pharmalucence — NDA Secondary Org
- Dec 16, 1977
Pharmalucence — NDA Organization
- Nov 28, 1978
Jubilant DraxImage Inc. — NDA Secondary Org
- Nov 28, 1978
Jubilant DraxImage Inc. — Marketing Organization
- Jun 26, 1979
General Electric — NDA Secondary Org
- Aug 29, 1979
Sun Pharmaceuticals — Marketing Organization
- Aug 29, 1979
Sun Pharmaceuticals — NDA Secondary Org
1980s
- Feb 17, 1981
Cardinal Health — NDA Secondary Org
Indications
Approved for
Mechanism of action
- BoneBINDING AGENT
Bone binding agent
Approval history
- approvedDec 16, 1977
Chemistry & pharmacology
- Mol. weight
- 290.91 g/mol
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral
- Availability
- Prescription Only
- Imaging
- 99-technetium
Oral
No
Parenteral
Yes
Topical
No
Sources
- ChEMBLCHEMBL1200931 ↗
- ChEMBLCHEMBL1200415 ↗
Also known as
- 99m tc medronate
- 99m tc medronate
- 99m tc-medronate
- 99m tc-medronate
- 99mtc medronate
- 99mtc medronate
- 99mtc-medronate
- 99mtc-medronate
- 99mtc-medronate
- amerscan mdp kit
- an-mdp
- an-mdp
- an-mdp
- cis-mdp
- cis-mdp
- cis-mdp
- draximage mdp-10
- draximage mdp-25
- draximage mdp-25
- draximage mdp-25
- mdp-bracco
- mdp-bracco
- mdp kit
- mdp kit
- osteolite
- osteolite
- osteolite
- osteolite
- oxidronic acid 99mtc-complex
- oxidronic acid 99mtc-complex
- tc 99m mdp
- tc 99m mdp
- tc-99m mdp
- tc-99m mdp
- tc-99m mdp
- tc 99m methylene diphosphonate
- tc 99m methylene diphosphonate
- technescan
- technescan
- technescan hdp
- technescan hdp
- technescan hdp
- technescan mdp
- technescan mdp
- technetium (99mtc) medronic acid
- technetium (99mtc) medronic acid
- technetium (99mtc) medronic acid
- technetium 99mtc medronic acid
- technetium 99mtc medronic acid
- technetium (99mtc) methylenediphosphonate
- technetium (99mtc) methylenediphosphonate
- technetium (99mtc) methylenediphosphonate
- technetium (99mtc) methylenediphosphonate for injection
- technetium (99mtc) oxidronate
- technetium (99mtc) oxidronate
- technetium 99mtc oxidronate
- technetium 99mtc oxidronate
- technetium (99mtc) oxidronic acid
- technetium methylene diphosphonate
- technetium methylene diphosphonate
- technetium tc 99m medronate
- technetium tc 99m medronate
- technetium tc 99m medronate
- technetium tc 99m medronate
- technetium tc 99m medronate
- technetium tc 99m medronate
- technetium tc-99m medronate
- technetium tc-99m medronate
- technetium tc-99m medronate
- technetium tc-99m medronate
- technetium tc-99m medronate
- technetium tc-99m medronate kit
- technetium tc-99m medronate kit
- technetium tc-99m medronate kit
- technetium tc-99m medronate kit
- technetium tc-99m medronate kit
- technetium tc 99m medronic acid
- technetium tc 99m medronic acid
- technetium tc 99m mpi mdp
- technetium tc 99m mpi mdp
- technetium tc 99m mpi mdp
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03107247 | Phase 4 | Aug 1, 2017 | Harvard University, Johns Hopkins University, National Institutes of Health (NIH), University of Florida |
| NCT01930812 | Phase 3 | Apr 1, 2014 | British Columbia Cancer Agency, Canadian Institutes of Health Research (CIHR) |
| NCT00956163 | Early Phase 1 (Phase 1) | Mar 1, 2010 | Harvard University, National Cancer Institute (NCI) |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Harvard University | Academic/Hospital | 2 | 1 | 2 | 2010 |
| British Columbia Cancer Agency | Academic/Hospital | 1 | 1 | 1 | 2014 |
| Canadian Institutes of Health Research (CIHR) | Academic/Hospital | 1 | 0 | 1 | 2014 |
| Johns Hopkins University | Academic/Hospital | 1 | 0 | 1 | 2017 |
| National Cancer Institute (NCI) | Government | 1 | 1 | 1 | 2010 |
| National Institutes of Health (NIH) | Government | 1 | 0 | 1 | 2017 |
| University of Florida | Academic/Hospital | 1 | 0 | 1 | 2017 |
7 organizations
Page 1 / 1
Marketing (8)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Cardinal Health | Academic/Hospital | NDA2 | Feb 17, 1981 |
| General Electric | For profit | NDA2 | Jun 26, 1979 |
| Jubilant DraxImage Inc. | For profit | NDA2 | Nov 28, 1978 |
| Jubilant DraxImage Inc. | For profit | MKTG | Nov 28, 1978 |
| Pharmalucence | For profit | NDA2 | Dec 16, 1977 |
| Pharmalucence | For profit | NDA | Dec 16, 1977 |
| Sun Pharmaceuticals | For profit | MKTG | Aug 29, 1979 |
| Sun Pharmaceuticals | For profit | NDA2 | Aug 29, 1979 |